Low dose IL-2 for neuromyelitis optica spectrum disorder
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study tests whether a low dose of a protein called IL-2 can safely help control the immune system in people with neuromyelitis optica spectrum disorder (NMOSD). It aims to reduce disease activity and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 74 years old.
- You must have a confirmed diagnosis of neuromyelitis optica spectrum disorder (NMOSD).
- Your disability level must be mild to moderate (scored between 0 and 6.5 on a standard scale).
- You must not have had major surgery in the past 4 weeks.
- You must not have active infections like hepatitis B, C, or tuberculosis.
- Your blood counts (white blood cells, lymphocytes, platelets) must be within normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a structured wellness program to improve quality of life for people with neuromyelitis optica (NMOSD). It is designed to be accessible for any level of disability.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
This trial tests whether an investigational drug called KSVCBD can safely reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). If you have had at least one relapse in the past year and meet other criteria, you may be able to join.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
This trial tests whether a low dose of a drug called IL-2 can help control both lupus and a common virus called cytomegalovirus (CMV). It may reduce lupus symptoms while helping your body fight off the virus.
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
Hear when a new Neuromyelitis Optica Spectrum Disorder (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.